DDInter170 DDInter1676
Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28,
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Bedaquiline {u} (Compound) resembles {v} (Compound) Bromodiphenhydramine
Bedaquiline {u} (Compound) resembles {v} (Compound) Orphenadrine
Bedaquiline {u} (Compound) binds {v} (Gene) CYP3A4
Bedaquiline {u} (Compound) is included by {v} (Pharmacologic Class) Diarylquinolines
Bedaquiline {u} (Compound) causes {v} (Side Effect) Arrhythmia
Bedaquiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dimethyl fumarate
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Bedaquiline {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Bedaquiline {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Bedaquiline (Compound) resembles Bromodiphenhydramine (Compound)
Bedaquiline (Compound) resembles Orphenadrine (Compound)
Bedaquiline (Compound) binds CYP3A4 (Gene)
Bedaquiline (Compound) is included by Diarylquinolines (Pharmacologic Class)
Bedaquiline (Compound) causes Arrhythmia (Side Effect)
Bedaquiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Bedaquiline may lead to a major life threatening interaction when taken with Clarithromycin
Bedaquiline may lead to a major life threatening interaction when taken with Glasdegib